A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
55-80 years
All
Phase
3
17 participants needed
1 Location
Brief description of study
The Study is two research trials aimed at preventing Alzheimer’s disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. AHEAD-3 studies people with intermediate amyloid, while AHEAD-45 studies people with elevated amyloid. Research studies are designed to gain scientific knowledge that may help people in the future.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Preclinical Alzheimer's diseaseElevated amyloidEarly preclinical Alzheimer's disease
-
Age: Between 55 Years - 80 Years
-
Gender: All
Male or female, age 55 to 80 years inclusive Study Partner
Updated on
01 Aug 2024.
Study ID: 842728
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
